Contact
searchSearch
HMP Global
Login

Oncology

Featured

FDA Approval
FDA Approves First Interchangeable Biosimilar to Pertuzumab for HER2-Positive Breast Cancer
11/13/2025
Stephanie Holland
The FDA approved pertuzumab-dpzb as the first interchangeable pertuzumab biosimilar for the treatment of patients with HER2-positive metastatic breast cancer.
The FDA approved pertuzumab-dpzb as the first interchangeable pertuzumab biosimilar for the treatment of patients with HER2-positive metastatic breast cancer.
The FDA approved pertuzumab-dpzb...
11/13/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
News
Effect of Dual PD-L1 Staining on PD-L1 Scoring in Non-Small Cell Lung Carcinomas
11/13/2025
Allison Casey
Dual PD-L1 staining may be easier to interpret but it had no significant impact on PD-L1 scoring when compared to mono staining.
Dual PD-L1 staining may be easier to interpret but it had no significant impact on PD-L1 scoring when compared to mono staining.
Dual PD-L1 staining may be...
11/13/2025
Oncology
News
Impact of Fine Needle Aspiration Collecting Medium on Success of Polymerase Chain Reaction Sequencing
11/13/2025
Allison Casey
According to a small cohort study, CytoRich Red performed better than formalin as a fine need aspiration collecting medium for PCR sequencing in cases of advanced non-small cell carcinoma.
According to a small cohort study, CytoRich Red performed better than formalin as a fine need aspiration collecting medium for PCR sequencing in cases of advanced non-small cell carcinoma.
According to a small cohort...
11/13/2025
Oncology
News
Real-World Practices and Challenges in Reflex Biomarker Testing at Diagnosis for Patients With Non-Small Cell Lung Cancer
11/13/2025
Allison Casey
Results from an online survey found that cancer care sites with standardized protocols and pathologist-ordered testing are more likely to adhere to clinical guidelines regarding comprehensive biomarker testing for patients with non-small cell...
Results from an online survey found that cancer care sites with standardized protocols and pathologist-ordered testing are more likely to adhere to clinical guidelines regarding comprehensive biomarker testing for patients with non-small cell...
Results from an online survey...
11/13/2025
Oncology
News
Impact of Specimen Requirements on Next-Generation Sequencing Testing for Lung Cancer
11/13/2025
Allison Casey
A drop in NGS adequacy rates for lung cancer occurred after a change in reference laboratories, potentially related to the specimen requirements of the new lab.
A drop in NGS adequacy rates for lung cancer occurred after a change in reference laboratories, potentially related to the specimen requirements of the new lab.
A drop in NGS adequacy rates for...
11/13/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology
News
Vorasidenib Sustains Clinical Benefit in IDH1/2-Mutant Glioma: Longer-Term Results From the INDIGO Trial
11/12/2025
Stephanie Holland
Longer-term results from the ongoing phase 3 INDIGO trial show vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency among patients with grade 2 IDH1/2-mutant diffuse glioma.
Longer-term results from the ongoing phase 3 INDIGO trial show vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency among patients with grade 2 IDH1/2-mutant diffuse glioma.
Longer-term results from the...
11/12/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology

Videos

Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology
Karen Yun, MD
Videos
Second-Line Treatment for HER2-Overexpressing Lung Cancer
11/06/2025
Karen Yun, MD
Karen Yun, MD, University of California, discusses the treatment of a patient with HER2-positive non–small cell lung cancer with disease progression in the liver, highlighting the role of trastuzumab deruxtecan as an effective targeted...
Karen Yun, MD, University of California, discusses the treatment of a patient with HER2-positive non–small cell lung cancer with disease progression in the liver, highlighting the role of trastuzumab deruxtecan as an effective targeted...
Karen Yun, MD, University of...
11/06/2025
Oncology
Jia Ruan, MD, PhD
Videos
Emerging Targeted Therapies for Peripheral T-Cell Lymphoma
11/06/2025
Jia Ruan, MD, PhD
Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.
Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.
Jia Ruan, MD, shares insights...
11/06/2025
Oncology
Alison Scram, MD
Videos
Zenocutuzumab Demonstrates Durable Responses in NRG1 Fusion-Positive Cholangiocarcinoma
11/05/2025
Alison Schram, MD
Alison Schram, MD, discusses results from the phase 2 eNRGy trial evaluating zenocutuzumab in patients with advanced NRG1 fusion–positive cholangiocarcinoma.
Alison Schram, MD, discusses results from the phase 2 eNRGy trial evaluating zenocutuzumab in patients with advanced NRG1 fusion–positive cholangiocarcinoma.
Alison Schram, MD, discusses...
11/05/2025
Oncology
Rebecca Dent, MD
Videos
Datopotamab Deruxtecan Improves Survival in Triple-Negative Breast Cancer
11/05/2025
Rebecca Dent, MD, discusses results from the phase 3 TROPION-Breast02 trial evaluating datopotamab deruxtecan versus investigator’s choice chemotherapy in patients with metastatic triple-negative breast cancer.
Rebecca Dent, MD, discusses results from the phase 3 TROPION-Breast02 trial evaluating datopotamab deruxtecan versus investigator’s choice chemotherapy in patients with metastatic triple-negative breast cancer.
Rebecca Dent, MD, discusses...
11/05/2025
Oncology

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology
News
Dabrafenib Plus Trametinib Shows Significant Clinical Benefit in BRAF V600E-Mutated Thyroid Cancer
11/07/2025
Stephanie Holland
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial...
11/07/2025
Oncology
Rebecca Dent, MD
Videos
Datopotamab Deruxtecan Improves Survival in Triple-Negative Breast Cancer
11/05/2025
Rebecca Dent, MD, discusses results from the phase 3 TROPION-Breast02 trial evaluating datopotamab deruxtecan versus investigator’s choice chemotherapy in patients with metastatic triple-negative breast cancer.
Rebecca Dent, MD, discusses results from the phase 3 TROPION-Breast02 trial evaluating datopotamab deruxtecan versus investigator’s choice chemotherapy in patients with metastatic triple-negative breast cancer.
Rebecca Dent, MD, discusses...
11/05/2025
Oncology
Geoffrey Liu, MD
Videos
Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
11/05/2025
Geoffrey Liu, MD
Geoffrey Liu, MD, discusses results from the phase 2 TRUST-2 trial evaluating taletrectinib in patients with ROS1-positive non-small cell lung cancer previously treated with entrectinib.
Geoffrey Liu, MD, discusses results from the phase 2 TRUST-2 trial evaluating taletrectinib in patients with ROS1-positive non-small cell lung cancer previously treated with entrectinib.
Geoffrey Liu, MD, discusses...
11/05/2025
Oncology
Anwaar Saeed, MD
Videos
Zanzalintinib Plus Atezolizumab Extends Survival in Metastatic Colorectal Cancer
11/05/2025
Anwaar Saeed, MD
Anwaar Saeed, MD, discusses results from the phase 3 STELLAR-303 trial evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with chemorefractory metastatic colorectal cancer who are not MSI-high or mismatch repair...
Anwaar Saeed, MD, discusses results from the phase 3 STELLAR-303 trial evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with chemorefractory metastatic colorectal cancer who are not MSI-high or mismatch repair...
Anwaar Saeed, MD, discusses...
11/05/2025
Oncology

Live Meetings

Recent News

FDA Approval
FDA Approves First Interchangeable Biosimilar to Pertuzumab for HER2-Positive Breast Cancer
11/13/2025
Stephanie Holland
The FDA approved pertuzumab-dpzb as the first interchangeable pertuzumab biosimilar for the treatment of patients with HER2-positive metastatic breast cancer.
The FDA approved pertuzumab-dpzb as the first interchangeable pertuzumab biosimilar for the treatment of patients with HER2-positive metastatic breast cancer.
The FDA approved pertuzumab-dpzb...
11/13/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
News
Effect of Dual PD-L1 Staining on PD-L1 Scoring in Non-Small Cell Lung Carcinomas
11/13/2025
Allison Casey
Dual PD-L1 staining may be easier to interpret but it had no significant impact on PD-L1 scoring when compared to mono staining.
Dual PD-L1 staining may be easier to interpret but it had no significant impact on PD-L1 scoring when compared to mono staining.
Dual PD-L1 staining may be...
11/13/2025
Oncology
News
Impact of Fine Needle Aspiration Collecting Medium on Success of Polymerase Chain Reaction Sequencing
11/13/2025
Allison Casey
According to a small cohort study, CytoRich Red performed better than formalin as a fine need aspiration collecting medium for PCR sequencing in cases of advanced non-small cell carcinoma.
According to a small cohort study, CytoRich Red performed better than formalin as a fine need aspiration collecting medium for PCR sequencing in cases of advanced non-small cell carcinoma.
According to a small cohort...
11/13/2025
Oncology
News
Real-World Practices and Challenges in Reflex Biomarker Testing at Diagnosis for Patients With Non-Small Cell Lung Cancer
11/13/2025
Allison Casey
Results from an online survey found that cancer care sites with standardized protocols and pathologist-ordered testing are more likely to adhere to clinical guidelines regarding comprehensive biomarker testing for patients with non-small cell...
Results from an online survey found that cancer care sites with standardized protocols and pathologist-ordered testing are more likely to adhere to clinical guidelines regarding comprehensive biomarker testing for patients with non-small cell...
Results from an online survey...
11/13/2025
Oncology
News
Impact of Specimen Requirements on Next-Generation Sequencing Testing for Lung Cancer
11/13/2025
Allison Casey
A drop in NGS adequacy rates for lung cancer occurred after a change in reference laboratories, potentially related to the specimen requirements of the new lab.
A drop in NGS adequacy rates for lung cancer occurred after a change in reference laboratories, potentially related to the specimen requirements of the new lab.
A drop in NGS adequacy rates for...
11/13/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology
News
Vorasidenib Sustains Clinical Benefit in IDH1/2-Mutant Glioma: Longer-Term Results From the INDIGO Trial
11/12/2025
Stephanie Holland
Longer-term results from the ongoing phase 3 INDIGO trial show vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency among patients with grade 2 IDH1/2-mutant diffuse glioma.
Longer-term results from the ongoing phase 3 INDIGO trial show vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency among patients with grade 2 IDH1/2-mutant diffuse glioma.
Longer-term results from the...
11/12/2025
Oncology
News
Consolidative Thoracic Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer After First-Line Chemoimmunotherapy
11/07/2025
Stephanie Holland
According to results from a retrospective analysis, administration of consolidative thoracic radiotherapy following first-line chemoimmunotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung...
According to results from a retrospective analysis, administration of consolidative thoracic radiotherapy following first-line chemoimmunotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung...
According to results from a...
11/07/2025
Oncology
News
Lower Ribociclib Dose Maintains Efficacy With Reduced Toxicity in Advanced HR-Positive, HER2-Negative Breast Cancer
11/07/2025
Stephanie Holland
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE...
11/07/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use